KRAS and colorectal carcinoma: Recently, results of a clinical trial (NCT03785249) have been published that show the efficacy of a combination therapy of adagrasib (KRAS p.(Gly12Cys) small molecule inhibitor) with cetuximab (anti-EGFR monoclonal antibody) for the treatment highly pretreated metastatic CRC patients26.